Clinical trial
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart…
NCT00159627 · NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00159627 |
|---|---|
| Title | Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Effects of KW-3902 on Diuresis in Patients With Congestive Heart Failure (CHF) Refractory to High Dose Diuretic Therapy |
| Lead sponsor | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | KW-3902IV |
| Enrollment | 52 |
| Start date | Aug 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 29, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: